AbbVie Declares Dividend and Announces Share Repurchase Program

Fri Feb 15, 2013 9:01am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link

NORTH CHICAGO, Ill.,  Feb. 15, 2013  /PRNewswire/ -- The board of directors of
AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend and also authorized
a share repurchase program of up to  $1.5 billion  of the Company's outstanding
common stock.

The cash dividend of  $0.40  per share is payable  May 15, 2013  to stockholders
of record at the close of business on  April 15, 2013.  AbbVie was named to the
S&P 500 Dividend Aristocrats Index, which tracks companies that have annually
increased their dividend for at least 25 consecutive years.  AbbVie was included
as a result of the Index's change in its treatment of spin-off companies.

The share repurchase authorization, which is effective immediately, is expected
to be completed over a multi-year period and purchases may be made from time to
time in management's discretion. The share repurchase authorization permits
shares to be repurchased in open market or private transactions, has no time
limit and may be discontinued at any time.

About AbbVie

AbbVie is a global, research-based biopharmaceutical company formed in 2013
following separation from Abbott. With its 125-year history, the company's
mission is to use its expertise, dedicated people and unique approach to
innovation to develop and market advanced therapies that address some of the
world's most complex and serious diseases. In 2013, AbbVie employs approximately
21,000 people worldwide and markets medicines in more than 170 countries. For
further information on the company and its people, portfolio and commitments,
please visit Follow  @abbvie  on Twitter or view careers on our
 Facebook or  LinkedIn  page.

Forward-Looking Statements

Some statements in this news release may be forward-looking statements for
purposes of the Private Securities Litigation Reform Act of 1995. AbbVie
cautions that these forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially from those
indicated in the forward-looking statements.  Economic, competitive,
governmental, technological and other factors that may affect AbbVie's
operations are discussed in the "Risk Factors" section of the Information
Statement attached to our Form 10 Registration Statement, which has been filed
with the SEC, and are incorporated by reference.  AbbVie undertakes no
obligation to release publicly any revisions to forward-looking statements as a
result of subsequent events or developments, except as required by law.

SOURCE  AbbVie Inc.

Media, Adelle Infante, (847) 938-8745, or Investors, Larry Peepo, (847)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.